Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EUSA Pharma Gains Foothold In U.S. Market With Cytogen Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Buyout positions U.K. drug maker to take on new licensing deals on both sides of the Atlantic; oncology filing planned within 12 months, EUSA tells the DAILY.

You may also be interested in...

EUSA Pharma Aims To Grow Through Acquisitions In Specialty Rx Market

EUSA Pharma announced the launch of operations March 23 with a group of products acquired from Jazz Pharmaceuticals and funding from equity investor Essex Woodlands; it is the third specialty pharma company set up by U.K. entrepreneur Bryan Morton.

Jazz Enters Oncology Market With EUSA Acquisition

Jazz strays away from its CNS focus with a $700 million acquisition of EUSA Pharma, adding the specialty pharma’s oncology product to its portfolio.

EUSA Wins U.S. Approval of Erwinaze; Shipping To Start Week Of Nov. 20

Eusa hopes the approval will help cement its efforts in the U.S., where it has been trying to build a strong presence for several years.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts